ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Randomised data will be needed to answer lingering questions about DKN-01.
Both BCMA-targeting Car-T therapies will face US advisory committee scrutiny after all.
The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
The first-line liver cancer Emerald-1 trial is positive, but only up to a point.